Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-250-0 | CAS number: 72619-32-0 HALOXYFOP R-(+)-ME HERBICIDAL CHEMICAL
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Objective of study:
- excretion
- metabolism
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.36 (Toxicokinetics)
- Deviations:
- no
- GLP compliance:
- yes
- Specific details on test material used for the study:
- 14C-Labeled R-haloxyfop methyl ester
Lot #: INV 1536
Radiochemical purity: 97.9%
Specific Activity: 18.3 mCi/mmole - Radiolabelling:
- yes
- Species:
- rat
- Strain:
- Fischer 344
- Details on species / strain selection:
- Fischer 344 rats were selected because of their general acceptance and suitability for toxicity testing, availability of historical background data, and the reliability of the commercial supplier, and the rat is the preferred species for pharmacokinetic/metabolism studies.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Inc. (Raleigh, North Carolina)
- Age at study initiation: 11 weeks
- Weight at study initiation: Males: 224-234 g and Females: 163-171 g
- Housing: The animals were housed 2 per cage in stainless steel cages
- Diet: PMI® Certified Rodent Lab Diet #5002, ad libitum except that feed was withdrawn from all animals approximately 21-hr prior to the administration of 14C-labeled test substance and returned about 1-hr post-dosing.
- Water: Municipal water, ad libitum
- Acclimation period: 7 days prior to start of the study. Prior to receiving the radiolabeled test substance, the animals were acclimated for four days in metabolism cages.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 ± 1
- Humidity (%): 50 ± 3
- Air changes (per hr): 12-15 times
- Photoperiod (hrs dark / hrs light): 12-hour light/dark - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The repeated dose solution was prepared in USP corn oil by the addition of unlabeled test substance. The solution was prepared at a target concentration of 0.05 mg test substance per g. The administration of ~2.2 mL per kg provided a dose level of 0.1 mg/kg. The radio labeled dose solution was prepared in USP corn oil by the addition of 14C-test substance. The solution was prepared at a target concentration of 0.05 mg test substance per g and 2.5 µCi per g. The administration of ~2 g per kg provided a dose level of 0.1 mg/kg and 1 µCi per rat.
- Duration and frequency of treatment / exposure:
- 14 daily oral doses of unlabeled test substance followed on the 15th day oral dose of 14C-labeled test substance
- Dose / conc.:
- 0.1 mg/kg bw/day
- Remarks:
- unlabeled test substance
- Dose / conc.:
- 0.1 mg/kg bw/day
- Remarks:
- 14C-labeled test substance
- No. of animals per sex per dose / concentration:
- 4
- Control animals:
- yes
- Details on study design:
- - Rationale for animal assignment: Animals were selected from those available using a computer-driven procedure that minimizes the differences between mean body weights within each sex by removing animals at the extremes of body weight range. The animals were identified by a uniquely assigned numbered metal eartag.
- Details on dosing and sampling:
- TOXICOKINETIC / PHARMACOKINETIC STUDY
- Tissues and body fluids sampled: urine, faeces, blood, plasma, tissues, cage washes
- Time and frequency of sampling: The urine traps were changed at 24-hr intervals for 7 days. The cages were rinsed with water at the time the traps were changed and the rinse collected. Feces were collected in dry-ice chilled containers at 24-hr intervals for 7 days. Seven days after dosing with the 14C-labeled test substance the animals were anaesthetized with CO2 and euthanized by exsanguination via cardiac puncture and tissues were collected. Following the terminal sacrifice of the animals, a final cage wash was performed. Blood was obtained at sacrifice via cardiac puncture. A sample of blood was centrifuged to obtain plasma and plasma analyzed for radioactivity. - Statistics:
- Descriptive statistics were used, (i.e., mean ± standard deviation). All calculations were conducted using Microsoft Excel® spreadsheets and databases in full precision mode (15 digits of accuracy). Log-linear regression analysis was used to estimate half-lives of elimination from the urine and feces interval 14C-excretion data.
Samples were considered non-quantifiable if dpm <2x background dpm. For non-quantifiable tissue samples, the quantitation limit (QL) value is displayed as NQ(QL). The mean will be calculated from all actual values and/or calculated QL values and expressed asstandard deviation, unless greater than half of the values are presented as NQ, in which case the mean will be expressed as NQ( standard deviation. If all of the values are NQ the mean will be presented as NQ( - Type:
- excretion
- Results:
- In total, females eliminated ~96% of the radioactivity while males eliminated ~54% of the radioactivity by 7 days post-dosing.
- Type:
- distribution
- Results:
- At sacrifice, males had ~43% of the radioactivity remaining in the carcass and tissues, with ~11% (~0.26 µg-eq/g) found in the liver.
- Details on distribution in tissues:
- Lesser amounts of 14C-activity were found in the carcass and tissues. At sacrifice, males had ~43% of the radioactivity remaining in the carcass and tissues, with ~11% (~0.26 µg-eq/g) found in the liver. Radioactivity in male tissues, in decreasing order of concentration, were liver, kidneys, plasma, whole blood, fat, skin, remaining carcass, and muscle. In females, only small amounts of radioactivity remained in the tissues 7 days post-dosing. The female kidneys, with <1% of the dose administered, had the greatest concentration of radioactivity (~0.02 µg-eq/g), Only small amounts of radioactivity were recovered in the other tissues from females, with muscle, skin, and remaining carcass below the QL of detection.
Comparison of the blood 14C concentration with the plasma 14C concentration suggests that the 14C-test substance-derived radioactivity is primarily distributed to the plasma. The whole blood concentration of radioactivity (0.094 and 0.005 µg eq./g blood, males and females, respectively) was lower than that obtained with plasma (0.151 and 0.007 µg eq./g blood, males and females, respectively). Since red blood cells and plasma are components of whole blood, removal of the red blood cells by centrifugation would have the apparent effect of concentrating the 14C-test substance-derived radioactivity in the plasma.- Details on excretion:
- Between 96 and 97% of the administered radioactivity was recovered. Radioactivity was excreted in the feces and urine, although a marked sex difference in the routes and rates of excretion was observed. In total, females eliminated ~96% of the radioactivity while males eliminated ~54% of the radioactivity by 7 days post-dosing.
During the first 24-hr post-dosing with the 14C-test substance, males excreted about 2% and females about 23% of the radio labeled dose in the urine. Through 168-hr post-dosing, males excreted a total of 12.4% of the dose in the urine, whereas females excreted 74.4% of the dose in the urine. A half-life for urinary elimination of 14C-test substance-derived radioactivity was calculated for males and females through 7 days post-dosing as 3.9 ± 0.6 and 1.0 ± 0.0 days, respectively.
Males excreted more of the administered radioactivity in the feces than females. Through 168-hr post-dosing, males excreted about 41.5% of the dose whereas females excreted 21.6% of the dose in the feces. A half-life for fecal elimination of 14C-test substance-derived radioactivity was calculated for each sex. The fecal half-lives of elimination were calculated as 3.9 ± 0.7 days and 1.8 ± 0.3 days for males and females, respectively.- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: The fecal half-lives of elimination were calculated as 3.9 ± 0.7 days and 1.8 ± 0.3 days for males and females, respectively.
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: A half-life for urinary elimination of 14C-test substance-derived radioactivity was calculated for males and females through 7 days post-dosing as 3.9 ± 0.6 and 1.0 ± 0.0 days, respectively.
- Metabolites identified:
- yes
- Remarks:
- haloxyfop acid and glucuronide conjugate of haloxyfop acid
- Details on metabolites:
- No unchanged parent was identified in the urine. The principle radioactive component of male and female urine was identified as haloxyfop acid (8.8% and 67.3% of administered dose for males and females, respectively). One additional metabolite present in female urine at 6.4% of the dose administered was tentatively identified as the glucuronide conjugate of haloxyfop acid.
Unchanged test substance was present at 3.7% and 8.2% of the administered dose in male and female feces, respectively. The principle radioactive component of male and female feces was identified as haloxyfop acid (37.9% and 13.4% of administered dose for males and females, respectively).Table-1: Distribution of radioactivity 168 hours after oral gavage administration of 14C-test substance to Fischer 344 rats (males)
Sample
Mean ± SD
Urine&Rinse
12.35 ± 1.19
Feces
41.50 ± 3.68
Carcass&Tissuesa
42.58 ± 3.19
Final Cage Wash
0.00 ± 0.00
Total
96.43 ± 4.58
Table-2: Distribution of radioactivity 168 hours after oral gavage administration of 14C-test substance to Fischer 344 rats (females)
Sample
Mean ± SD
Urine & Rinse
74.37 ± 2.62
Feces
21.65 ± 2.83
Carcass & Tissuesa
1.02 ±0.20
Final Cage Wash
0.42 ± 0.85
Total
97.46 ± 1.11
a Liver, skin, whole blood, kidney, muscle, fat and remaining carcass
Table-3: Interval and cumulative excretion in urine of 14C-test substance-derived radioactivity by male and female Fischer 344 rats
Male rats
Female rats
Time (hr)
Sample
Interval
Cumulative
Sample
Interval
Cumulative
0-24
Rinse
0.18 ± 0.05
Rinse
2.03 ± 0.86
Urine
1.71 ± 0.20
Urine
20.95 ± 9.20
Subtotal
1.89 ± 0.25
1.89 ± 0.25
22.98 ± 9.63
22.98 ± 9.63
24-48
Rinse
0.36 ± 0.15
Rinse
1.71 ± 0.47
Urine
2.34 ± 0.25
Urine
20.78 ± 2.07
Subtotal
2.70 ± 0.37
4.59 ±0.56
22.50 ± 1.82
45.47 ±11.43
48-72
Rinse
0.17 ± 0.04
Rinse
1.39 ± 1.02
Urine
1.98 ± 0.01
Urine
12.88 ± 4.11
Subtotal
2.15 ± 0.03
6.74 ± 0.57
14.28 ± 4.99
59.75 ± 6.79
72-96
Rinse
0.24 ± 0.08
Rinse
0.86 ± 0.56
Urine
1.63 ± 0.17
Urine
7.81 ± 3.56
Subtotal
1.87 ± 0.25
8.61 ± 0.80
8.67 ± 4.05
68.42 ± 3.90
96-120
Rinse
0.16 ± 0.09
Rinse
0.37 ± 0.34
Urine
1.24 ± 0.14
Urine
3.35 ± 1.80
Subtotal
1.40 ± 0.19
10.00 ± 0.99
3.71 ± 2.12
72.13 ± 2.50
120-144
Rinse
0.25 ± 0.09
Rinse
0.17 ± 0.15
Urine
0.97 ± 0.08
Urine
1.07 ± 0.44
Subtotal
1.22 ± 0.11
11.22 ± 1.09
1.24 ± 0.54
73.37 ± 2.71
144-168
Rinse
0.20 ± 0.05
Rinse
0.19 ± 0.06
Urine
0.93 ± 0.13
Urine
0.81 ± 0.13
Subtotal
1.13 ± 0.16
12.35 ± 1.19
1.00 ± 0.11
74.37 ± 2.62
Grand total
12.35 ± 1.19
74.37 ± 2.62
- Conclusions:
- Haloxyfop acid was identified in male and female urine (~9% and 67% of administered dose for males and females, respectively) and feces (~38% and 13% of administered dose for males and females, respectively), and male liver and kidney (~11 % and ~2% of dose administered, respectively). The glucuronide conjugate of haloxyfop acid was also identified in female urine (~6% of dose administered). A small amount of test substance was recovered in the feces of both male and female rats (~4% and ~8% of dose administered, respectively).
- Executive summary:
The purpose of this study was to provide data on the metabolism and elimination of 14C-test substance following repeated oral gavage administration of test substance to rats. The study was conduted following OECD guideline 417 and EU method B.36. Four male and four female Fischer 344 rats were given 14 daily 0.1 mg/kg oral doses of unlabeled test substance followed on the 15th day by a 0.1 mg/kg oral dose of 14C-Iabeled test substance. The study continued for 7 days following dosing with the 14C-Iabeled test substance.
Between 96 and 97% of the administered radioactivity was recovered. The data indicate that radioactivity derived from the orally administered 14C-R-test substance was efficiently absorbed by both male and female rats with at least 55% and 75%, respectively, of administered radioactivity recovered in the urine, carcass, and tissues. Additionally, 38% and 13% of the dose, males and females, respectively, was recovered in the feces as haloxyfop acid and likely represents absorbed radio labeled material. Therefore, at least 93% and 88% of the administered radioactivity was absorbed in males and females, respectively.
A marked sex difference in the routes and rates of excretion was observed. Through 168 hr post-dosing, males excreted ~12% in the urine, whereas females excreted ~74% in the urine. A half-life for urinary elimination of 14C-test substance-derived radioactivity was calculated for males and females through 7 days post-dosing as 3.9 and 1.0 days, respectively. Males excreted more of the administered radioactivity in the feces than females. Through 168 hr post-dosing, males excreted ~42% whereas females excreted ~22% in the feces. Half-lives for faecal elimination of 14C-test substance-derived radioactivity were calculated for each sex as 3.9 and 1.8 days for males and females, respectively.
At sacrifice, males had ~43% of the radioactivity remaining in the carcass and tissues, with ~11 % (~0.26 µg eq./g) found in the liver. Radioactivity in males tissues, in decreasing order of concentration, were liver, skin, whole blood, kidneys, muscle and fat. In females, only small amounts of radioactivity remained in the tissues 7 days post-dosing. The female liver, with <1% of the dose administered, had the greatest concentration of radioactivity (~0.02 µg eq./g). Only small amounts of radioactivity were recovered in the other tissues from females, with muscle, skin, and remaining carcass below the limit of detection. Pooled samples of male and female urine, faeces, plasma, kidney, and liver were analysed by reversed-phase, high performance, liquid chromatography. There were a total of four radioactive peaks detected in the matrices. No sample contained all four peaks. Based on retention-time comparisons with authentic standards, haloxyfop acid was identified in male and female urine (~9% and 67% of administered dose for males and females, respectively) and feces (~38% and 13% of administered dose for males and females, respectively), and male liver and kidney (~11 % and ~2% of dose administered, respectively). The glucuronide conjugate of haloxyfop acid was also identified in female urine (~6% of dose administered). A small amount of test substance was recovered in the feces of both male and female rats (~4% and ~8% of dose administered, respectively).
Reference
Description of key information
Key value for chemical safety assessment
Additional information
A rat study was conducted to provide data on the metabolism and elimination of 14C-test substance following repeated oral gavage administration of test substance. The study was conducted following OECD guideline 417 and EU method B.36. Four male and four female Fischer 344 rats were given 14 daily 0.1 mg/kg oral doses of unlabeled test substance followed on the 15th day by a 0.1 mg/kg oral dose of 14C-Iabeled test substance. The study continued for 7 days following dosing with the 14C-Iabeled test substance. Haloxyfop acid was identified in male and female urine (~9% and 67% of administered dose for males and females, respectively) and feces (~38% and 13% of administered dose for males and females, respectively), and male liver and kidney (~11 % and ~2% of dose administered, respectively). The glucuronide conjugate of Haloxyfop acid was also identified in female urine (~6% of dose administered). A small amount of test substance was recovered in the feces of both male and female rats (~4% and ~8% of dose administered, respectively).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.